Bausch + Lomb Corp

NYSE:BLCO  
15.31
-0.30 (-1.92%)
Products

Bausch + Lomb And Novaliq Announce U.S. FDA Filing Acceptance For Investigational Treatment Nov03 (Perfluorohexyloctane)

Published: 09/06/2022 11:58 GMT
Bausch + Lomb Corp (BLCO) - Bausch + Lomb and Novaliq Announce U.S. FDA Filing Acceptance for Investigational Treatment Nov03 (perfluorohexyloctane).
Bausch + Lomb Corp - PDUFA Action Date is June 28, 2023.